PolyPid announced that the first patient has been enrolled and randomized in a Phase 3 clinical trial called SHIELD (Surgical site Hospital acquired Infection prEvention with Local D-plex).
PolyPid has completed patient enrollment of 200 patients in its Phase 2 clinical trial evaluating D-PLEX100 for the prevention of post-abdominal surgery incisional site infections.